The pathophysiological role for the expression of human chorionic gonadotrophin (hCG) in malignant neoplasms is currently speculative. We investigated the overall expression of genes hCG-5, 3, 8 and 7 in breast carcinoma (n=214), fibroadenoma (n=37) and macromastia (n=10) by quantitative reverse transcriptase-PCR. Eighty (37·4%) of the breast cancer samples revealed positive hCG-mRNA expression and the mean value was 67·9 copies per 200 ng total RNA (range: 0-1743; 95% confidence interval (CI) for mean: 44-92). Fibroadenomas had more frequently detected (56·8%) and greater hCG-copy numbers (mean 86·9; range: 0-845; 95% CI for mean: 35-138). Macromastia probes yielded no positive hCG-mRNA. The hCG-mRNA expression was significantly different in the three histological subgroups (P=0·006). Among breast carcinomas, a positive correlation was detected between hCGmRNA copy numbers and progesterone receptor (PgR) values (P<0·001). No significant differences were seen regarding disease-free (P=0·87) and overall survival (P=0·20) depending on hCGmRNA status. Finally, our findings do not support a role for hCG-in malignant transformation of human breast cells and indicate a possible involvement of hCG-in benign breast disease. The relationship with PgR expression may suggest that progestins regulate the expression of hCG in breast epithelial cells.
INTRODUCTION
Fibroadenoma is the most common benign breast tumour, most frequently presenting in women 20-50 years old. Breast cancer is the most frequent malignancy in women, and the leading cause of death among women who are 40-55 years of age. The lifetime odds of developing breast cancer are apparently up to 1 in 8 in North America and 1 in 12 in Western Europe (Brzezinski & Schenker 1997) . No reduction in the mortality rate has resulted from advances in early diagnosis and new therapeutic modalities; therefore, new approaches to the understanding of this disease are required.
Human chorionic gonadotrophin (hCG) is a glycoprotein hormone consisting of two noncovalently linked subunits. The free hCG-and hCG-proteins are encoded by several independent genes and combine to form the biologically active intact hCG molecule (Fiddes & Goodman 1980 , Boorstein et al. 1982 , Policastro et al. 1983 . hCG and its free subunits are produced by both trophoblastic and many nontrophoblastic tumours. The free subunit of hCG protein is the predominant form produced by nontrophoblastic tumours, although serum levels are virtually undetectable due to the very short half-life (2·4 h) (Carter et al. 1994) .
The hCG-subunit is encoded by a multigene cluster on chromosome 19 composed of six homologous sequences (genes or pseudogenes). They are primarily distinguished by sequences in the 5 -nontranslated region of the first exon. It seems likely that all these genes are transcribed, although most of the mRNAs in vivo are transcripts from genes 5, 3 and 8 (Bo & Boime 1992) . Only genes 5, 3, 8 and 7 present the open reading frame of the hCG-subunit protein. The other two genes 1 and 2 are considered pseudogenes because they contain a several hundred base pairs (bp) insertion that replaces the promoter and most of the 5 -untranslated region (Policastro et al. 1983) .
The pathophysiological role for the expression of hCG in malignant neoplasms is currently speculative. hCG expression may represent recapitulation of fetal cell properties by malignant cells (Acevedo et al. 1995) . Several authors have suggested that the hCG-subunit might have antiangiogenic activity or might induce apoptosis (Gill et al. 1996 , Krown 1996 . Recently, hCG-mRNA was detected not only in malignant breast cells but also in normal breast cells (Bellet et al. 1997) .
The aim of our study was to determine if there are quantitative differences in hCG-mRNA expression between benign and malignant breast disease. We investigated the overall expression of genes hCG-5, 3, 8 and 7 in patients with breast carcinoma, fibroadenoma and macromastia by quantitative reverse transcriptase-PCR (RT-PCR). Possible correlations with clinical parameters and prognostic factors are analysed. In the past, only methods for qualitative or semiquantitative evaluation of hCG-mRNA levels were available. Our assay, which detects the absolute mRNA copy number, may greatly improve differentiation within the positive samples and accurately define cut-off values.
MATERIALS AND METHODS

Patient data
Primary breast carcinoma specimens were obtained from 214 unselected patients treated at the University of Rostock Women's Hospital from 1994 to 1999. These patients (mean age: 58·5 years, range: 29-90 years) were included for the following criteria: primary unilateral breast carcinoma, no other primary cancer or metastasis, no radiation therapy or chemotherapy before surgery, and complete collection of clinical data. All carcinoma patients of this study underwent either total or partial axillary lymph node dissection (mean number of nodes examined, 18). The main classifying prognostic factors are presented in Table 1 . One hundred and six women (49·5%) were treated with simple mastectomy and lymph node dissection, 108 (50·5%) with lumpectomy plus axillary clearance. One hundred and seventy-five tumours (81·8%) were infiltrating ductal carcinomas. Breast-conserving surgery was followed by postoperative radiotherapy (n=97). One hundred and ninety-six patients received adjuvant therapy, consisting of chemotherapy (n=46), hormone therapy (n=95) or both (n=55). The median follow-up was 30 months (range: 6-57 months). The cut-off date for this analysis was July 1999.
Breast tissue from 37 patients with fibroadenoma (mean age: 39·7 years, range: 15-67 years) and 10 women with macromastia (mean age: 30·6 years, range: 20-43 years) was also studied. Women with multiple fibroadenomas were excluded. Within the fibroadenoma subgroup, the mean tumour size was 21 mm (range: 12-45 mm; 95% confidence interval (CI) for mean: 17·3-24·5 mm). Selected demographic data of all 214 patients are listed in Table 2 .
Tissue samples
Tissues were obtained from patients who underwent surgery at our hospital in accordance with protocols approved by the human studies committee of our institution. Normal or pathological tissue areas were dissected from each surgical specimen, and histology was routinely determined by visual examination. The steroid hormone receptor status of each tumour and the number of negative or positive axillary lymph nodes were assessed at the time of surgery. Oestrogen and progesterone receptors (ER, PgR) were determined by radioligand assays (dextran-coated charcoal method), with a cut-off value of 10 fmol/mg cytosolic protein.
All tissue samples were stored in a liquid nitrogen tissue bank until used.
RNA extraction
Total RNA was prepared using the acid guanidinium thiocyanate-phenol-chloroform protocol (Chomczynski & Sacchi 1987) . The quality of the RNA samples was determined by electrophoresis through denaturing agarose gels and staining with ethidium bromide. The RNA was quantified and evaluated for purity by UV spectrophotometry. To further assess the quality of RNA, all specimens were tested by analysis of housekeeping gene expression using conventional RT-PCR. Firsttrimester placenta served as positive control and was obtained from women undergoing legal abortions.
Primer and probe design
hCG-primers and probe were designed using the Primer Express 1·0 program (PE Applied Biosystems, Foster City, CA, USA). Oligonucleotide hybridization probe and primers with the following sequences were synthesized as follows: TaqMan probe 5 -CTG CTG AGC ATG GGC GGG ACA T (exon 2), forward primer 5 -CCA AGG ATG GAG ATG TTC CAG and reverse primer 5 -GCA CGC GGG TCA TGG T. The reverse primer was designed to span an exon/intron junction to avoid amplification of DNA sequences, whereas the forward primer was complementary to the 3 -end of exon 1. Primers and probe were obtained from Applied Biosystems GmbH (Weiterstadt, Germany).
hCG-oligonucleotides were developed based on previously published data (Policastro et al. 1986 , Bo & Boime 1992 , Lazar et al. 1995 to amplify the hCG-5, 8, 3 and 7 mRNA, without amplification of hCG-1, hCG-2 or luteinizing hormone (LH)-mRNA. The primers yielded a RT-PCR product of 199 nucleotides. 
hCG-transcripts in breast tumours ·   and others
The forward primer and probe have only a 1 bp mismatch, and the reverse primer has a 2 bp mismatch with the LH-gene. Although the nucleotide sequences of hCG-and LH-are 94% homologous, we excluded an amplification of LHtranscripts by DNA sequencing (ABI PRISM 310 Genetic Analyzer; PE Applied Biosystems).
Preparation of RNA standard
For calibration of the hCG-TaqMan-assay an RNA standard was generated by using an in vitro T7-polymerase transcription system (RiboMAX Large Scale RNA Production System; Promega, Madison, WI, USA).
Using the TaqMan 5 -and 3 -primers a preparative standard PCR reaction was performed to produce an hCG--specific DNA fragment. The cloning procedure was carried out by ligating this fragment into an SmaI linearized pBLUESCRIPT KS vector (Stratagene, La Jolla, CA, USA). The correct plasmid clone was purified by ionic exchange column DNA preparation (Qiagen, Valencia, CA, USA) and linearized by XhoI cleavage to generate a useful template for producing a cut-off in vitro transcript.
A starting mixture was made by diluting the specific RNA molecules with a competitor yeast tRNA (Life Technologies, Grand Island, NY, USA) to a final concentration of 10 10 in vitro transcripts in 2 µg yeast tRNA per 10 µl (in water). This starting mixture was used to prepare stock dilution series over eight logs from 10 9 to 10 2 hCG--specific RNA molecules. Finally, we prepared eight different calibration amounts of the specific RNA molecules extending from 10 8 to 10
1 .
RT-PCR procedure
The TaqMan EZ RT-PCR Kit (PE Applied Biosystems) was used for reverse transcription and amplification of both targets and standards. All RT-PCR reactions were performed in duplicate with a final volume of 50 µl. RT-PCR conditions were optimized for primers (300 nM), probe (100 nM), template (200 ng) and manganese acetate concentrations (3 mM). The reaction conditions were 2 min at 50 C, 30 min at 60 C, 5 min at 95 C, 45 cycles with 20 s at 94 C and 1 min at 60 C.
Quantification of hCG-mRNA expression
PCR assays were performed in a 96-well microtitre plate format on an ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems). The first two lanes contained serial dilutions of the prepared standard with known amounts of input RNA molecules to create a standard curve. The quantification of hCG-RNA standard was linear over eight logs and the assay could measure as little as 100 copies of hCG-mRNA copies per tube. In all experiments the correlation coefficient of the standard curve was between 0·985 and 0·995.
Statistical methods
Clinical, histological and biological parameters were compared using the most appropriate among the Spearman correlation coefficient, 2 test, MannWhitney U test and Kruskal-Wallis H test. Disease-free and overall survival were analysed using the Kaplan-Meier method, and comparison of study groups was performed with the log-rank test. The Cox regression model was applied over both univariate and multivariate analyses, with the associated likelihood ratio test used for tests of trend differences. In all tests, the significance level was set at P<0·05, and all were two-tailed tests.
RESULTS
Expression of hCG-mRNA in subgroups
The quantitative range of hCG-mRNA copy numbers per 200 ng total RNA in breast carcinoma, fibroadenoma and macromastia is presented in Fig. 1 . Eighty (37·4%) of the breast cancer samples revealed positive hCG-mRNA expression. The mean value for all 214 breast carcinoma patients was 67·9 copies per 200 ng total RNA (range: 0-1743; 95% CI for mean: 44-92). Patients with fibroadenoma (n=37) had higher hCG-copy numbers (mean 86·9; range: 0-845; 95% CI for mean: 35-138). In contrast to malignant breast tissue, hCG-mRNA was detectable in 56·8% of all fibroadenomas (n=21). All probes of women with macromastia (n=10) yielded no positive result for hCG-mRNA expression. The pattern of hCGmRNA expression was significantly different in the three histological subgroups (P=0·006).
Relationship between hCG-mRNA and other variables in breast carcinoma
Among 214 breast cancers, no correlation was found between hCG-mRNA copy number and tumour size, histopathological grading, stage, histology, lymph nodes status, ER status and menopausal status (Table 1) . A positive correlation was detected between hCG-mRNA copy numbers and PgR values (P<0·001) and PgR status (P<0·001) respectively. The Mann-Whitney U test confirmed the higher PgR levels in hCG-positive tumours compared with hCG-mRNA negative carcinomas (P<0·0001; Fig. 2) .
Furthermore, evaluation of an association between hCG-mRNA copy numbers and epidermal growth factor receptor (P=0·727), cathepsin D (P=0·812), vascular (P=0·631) or lymphatic invasion (P=0·138), body mass index (BMI) (P=0·172), age (P=0·16) or pregnancy rate (P=0·622) revealed no correlations. Age of menarche and hCG-mRNA copy numbers revealed a negative correlation (P=0·022).
No significant differences in disease-free (P=0·87) and overall survival (P=0·20) were detected regarding hCG-mRNA positive or negative tumours using the Kaplan-Meier method (Figs 3 and 4) . To compare independent prognostic impact, hCG-mRNA status was combined with  1. Box-plot diagram of hCG-mRNA copy numbers per 200 ng total RNA in 214 breast carcinomas, 37 fibroadenomas and 10 macromastia (P=0·006). The boxes represent the range between the 25th and 75th percentiles with a horizontal line at the median. The bars delineate the 5th and 95th percentiles. The circle () and asterisk indicate extreme values (=more than 1·5 box lengths from the 75th percentile and *=more than 3·0 box lengths from the 75th percentile).  4. Overall survival curve for breast cancer patients with positive and negative hCG-mRNA status.
hCG-transcripts in breast tumours ·   and othersthe established prognostic factors in a Cox regression analysis for disease-free and overall survival (Table 3) . Histological grading (P=0·018) and tumour size (P=0·033) were significantly related to disease-free survival in the univariate analysis. Among these factors only grading (P=0·022) was of independent significance in the multivariate model. Using the described approach for overall survival analysis, tumour size (P=0·0027) and histological grading (P=0·003) were significant prognostic factors in the univariate test. Tumour size (P=0·01) and grading (P=0·001) were also independent prognostic parameters for overall survival in the multivariate model.
Relationship between hCG-mRNA and other variables in fibroadenoma
Among 37 fibroadenomas, significantly higher copy numbers of hCG-mRNA were observed in women who were nulligravidas compared with patients who had had one or more pregnancies (P=0·0354). No association was seen between hCG-mRNA copy numbers and tumour size (P=0·091), age (P=0·642), BMI (P=0·114), pregnancy rate (P=0·233), day of menstrual cycle (P=0·2573) or age of menarche (P=0·855).
DISCUSSION
hCG is a glycoprotein hormone normally secreted early in pregnancy whose molecular structure and functions are quite similar to those of LH secreted by the pituitary. Its better known function is to prevent the normal involution of the corpus luteum in the ovary by stimulating the synthesis and secretion of oestrogen, progesterone and inhibins (Woodruff & Mayo 1990) . However, recent evidence shows that in addition to its classical endocrine effects, hCG may also be ectopically synthesized and exert paracrine effects regulating the growth of various cell types.
The ectopic production of hCG protein was found in patients with carcinomas of the stomach, liver, pancreas and breast and with multiple myeloma and melanoma (Braunstein et al. 1973) . On the mRNA level, Yokotani et al. (1997) suggest the production of hCG-genes as being part of the phenotype of malignantly transformed lung cells. Lazar et al. (1995) have used hCG-transcripts as a prognostic marker, because the transcription levels of hCG-genes 5, 8 and 3 increased with the stage of bladder carcinomas. The expression of hCG-by bladder tumours seems to be the result of altered gene regulation and not a rearrangement or amplification of the hCG--LH gene cluster (Iles et al. 1989) .
The pathophysiological role of ectopic hCG production in the mammary gland is still unclear. Molecular techniques and immunohistochemical methods indicate that the hCG-transcripts are translated in breast tumour cells and that hCGprotein is thereby secreted. In earlier reports, opinions differed on whether the immunoreactive hCG-protein is produced in situ by the tumour cells or has to be considered as a plasmatic contamination. Indeed, there is some evidence of hCG-protein secretion by human lymphocytes in a mixed lymphocyte culture (Harbour-McMenamin et al. 1986 ). However, numerous immunohistochemical studies revealed that the hCG positivity is clearly located in tumour cells and not in macrophages. Hoon et al. (1996) showed hCG-mRNA expression in seven breast cancer cell lines, although only three of these cell lines secreted detectable levels of hCG protein. Wachner et al. (1984) detected hCG-in 16 breast carcinomas out of 129 (12%) and in 2 benign breast lesions out of 39 (5%). The normal breast and normal lactating breast tissues studied were both negative for hCG-. In most of the tumours only very few cells (less than 1%) contained hCG-protein. This fact may explain the low mean values of hCG-mRNA copy numbers in our study (mean of breast carcinomas: 68 copies per 200 ng total RNA; mean of fibroadenomas: 85 copies). Russo & Russo (1994) showed that hCG was able to induce a protective effect on rat mammary carcinogenesis and that the effect was dose dependent. After carcinogen administration, rats treated with hCG developed both benign and malignant tumours, but their incidence and the number of tumours per animal were significantly decreased by hormonal treatment. The authors suggest that inhibin mediates the differentiating action of both pregnancy and hCG on the mammary gland. Srivastava et al. (1998) analysed the inhibitory effects of hCG in human breast epithelial cells and suggested that hCG induces an acceleration in the expression of apoptotic genes, which become evident before detection of cell growth inhibition.
Pregnancy, and especially early pregnancy, have been shown to be protective for breast cancer (Kelsey et al. 1993) . In this case, we expected an association between hCG-mRNA copy numbers and benign histology or low malignant breast carcinomas. Our results confirmed this hypothesis in part. The detection of hCG-transcripts of protein-coding genes is more frequent and quantitatively higher in benign breast tumours compared with breast carcinomas. For the first time, we have found significant quantitative differences in hCG-mRNA expression among benign and malignant breast tumours. These findings do not support a role for hCG-in malignant transformation of human breast cells and suggest a possible involvement of hCG-in benign breast disease. Hoon et al. (1996) detected in 80% of investigated primary breast cancer tumour biopsies (n=20) positive hCG-mRNA by RT-PCR. Our percentage of positive hCG-carcinoma samples in a larger study (n=214) is only 37%. Otherwise, we confirmed that no hCG-transcripts were found in normal breast tissue obtained after cosmetic surgery. To our knowledge, no previous publication has reported expression of hCG-mRNA in fibroadenoma.
Using the Kaplan-Meier method and Cox regression model, the hCG-mRNA status of breast carcinomas was not a prognostic factor for disease-free or overall survival. However, a longer follow-up is necessary for final evaluation.
Among 214 breast cancer specimens, we have found a positive correlation between hCG-mRNA copy numbers and biochemical PgR values. In pregnant women, we assume this association in the ovary and the uterus. Iwai et al. (1991) studied the immunohistochemical expression of both ER and PgR in the ovary and the uterus of mature rabbits during the induction of ovulation by folliclestimulating hormone followed by administration of hCG, progesterone or a progesterone antagonist and hCG. The results suggest that the expression of ER and PgR in granulosa cells is not regulated by the action of progesterone, but by that of LH/hCG. Within mammary carcinomas, the correlation of hCG-transcripts and positive PgR status is unexpected. The relationship with PgR expression may suggest that progestins regulate the expression of hCG in breast epithelial cells. Horwitz & McGuire (1975) described the presence of specific receptors for progesterone in human breast cancer tissue and later demonstrated that these were controlled by oestradiol via ERs (Horwitz & McGuire 1978) . The role of PgR in breast tumour cell growth is apparently complex; it has been shown to affect insulin receptors, growth hormone receptors, epidermal growth factor receptors and lactogenic receptors (Carpenter 1988) .
ER and PgR assays are the factors most predictive for hormone therapy. However, the effect of progestogens on the development of human breast cancer is still unclear; in vivo studies of progestins have been shown to both stimulate and inhibit breast cell proliferation at physiological concentrations (Staffa et al. 1992) . Approximately 40% of primary breast tumours are positive for both ER and PgR while <5% are positive for PgR alone -an expected result, if PgR is regulated by oestrogen. Premenopausal patients have higher PgR levels, which are probably induced by the higher oestrogen concentrations (Osborne 1998) .
Our investigations might indicate the involvement of hCG as a growth regulating factor in breast cells via steroidgenesis and PgR. The PgR-related processes may occur in benign and malignant breast tumours, because various authors have described positive PgR values in benign breast disease as well. The PgR is detectable more frequently than the ER in patients with fibroadenomas, with an overall positive PgR status between 44 and 48% (Meissner et al. 1989 , Jaquemier et al. 1990 .
A direct action of hCG on benign and malignant breast tumours implies the existence of the corresponding receptor in these tissues. Recently, functional LH/hCG receptors were detected in breast cancer cell lines, in cancer biopsies and in hCG-transcripts in breast tumours ·   and othersbenign breast lesions (Lojun et al. 1997 , Meduri et al. 1997 . Currently, ectopic hCG-expression is not only important for research in tumour biology but for therapy trials as well.
